Sarepta Therapeutics Inc

Sarepta Therapeutics Inc. is facing a financial and ethical crisis after a series of safety concerns and patient deaths linked to its gene therapy product, Elevidys, caused its stock price to plummet.

Sarepta Therapeutics Inc has announced a comprehensive restructuring plan to bolster long-term growth and sustainability, boosting investor confidence and sparking a 35% surge in its stock price.

Sarepta Therapeutics Inc’s stock plummeted by over 40% after a second patient death linked to its gene therapy, Elevidys, raising concerns about the therapy’s safety profile and the company’s future prospects.

Sarepta Therapeutics is a leading biotech company pioneering RNA-based therapeutics, poised to revolutionize the treatment of rare and infectious diseases with its innovative approaches.

Sarepta Therapeutics, a biotechnology company, is a leader in RNA-based therapeutics, driven by a mission to revolutionize the treatment of rare and infectious diseases.